BEAM
BEAM
Indizes, Rohstoffe, Movers, Heatmap und Top-Stories. Ohne Login.
BEAM
BEAM NASDAQ
Insider Selling: Beam Therapeutics (NASDAQ:BEAM) CEO Sells $589,250.00 in Stock
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a Fuse
Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress
Umsatz & Nettogewinn (5J)
EPS & Wachstum (5J)
Free Cash Flow (5J)
Kapitalrendite
Operating- & Nettomarge (5J)
CapEx vs. Free Cashflow (5J)
Kapitalallokation (5J)
F&E- und SG&A-Intensität (5J)
EBITDA (5J)
Umsatzkosten (5J)
Marktkapitalisierung (5J)
Frag Blinx mit professionellen Marktdaten, Charts neben dem Chat und deinem Depot-Kontext.
Standard sind Lang & Schwarz Kurse. NASDAQ ist der verzögerte Listing-Kurs. Charts bleiben Tageskurse. Keine Anlageberatung.